Samsung Biologics recently completed the spin-off of Samsung Bioepis, reinforcing its strategic focus as a pure-play CDMO. With combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, and 60,000 liters from an acquisition of a Maryland facility, the company leverages cutting-edge technologies to advance diverse modalities including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. The company received EcoVadis' Platinum Sustainability Rating in January 2026, placing it in the top one percent of companies evaluated globally.
With a market capitalization of $54.5B and trailing 12-month revenue of $3.9B, Samsung Biologics demonstrates substantial scale in the CDMO market. In 2024, the company achieved revenue of 4.55 trillion KRW (23% growth) and earnings of 1.08 trillion KRW (26% growth). Strategic expansion with the GSK Human Genome Sciences acquisition and recent spin-off positioning enhance competitive positioning.
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.
Open report →